Literature DB >> 18568853

The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis.

William Cruz-Munoz1, Rama Khokha.   

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) are classically known for regulating members of the metzincin protease family and are well recognized for their inhibitory effects in cancer development and progression. Despite their common evolutionary structure, the four TIMP proteins have unique properties and regulation, and produce distinct phenotypes when ablated. A comprehensive assessment of their function during tumorigenesis reveals substantial effects on cell proliferation, apoptosis, angiogenesis, invasion, and metastasis as well as a potential role in genomic instability. The TIMPs universally inhibit angiogenesis, invasion, and metastasis, but their specific effects on cell proliferation and apoptosis are both tissue specific and context dependent. They exert these effects in a metalloproteinase-dependent as well as metalloproteinase-independent manner. Knowledge gained from these biological studies provides a foundation for the full understanding of TIMP function in physiology and various pathologies as well as for the development of the next generation of therapeutic metalloproteinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568853     DOI: 10.1080/10408360801973244

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  52 in total

Review 1.  The extracellular matrix at a glance.

Authors:  Christian Frantz; Kathleen M Stewart; Valerie M Weaver
Journal:  J Cell Sci       Date:  2010-12-15       Impact factor: 5.285

2.  Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.

Authors:  Masayuki Shimoda; Simona Principe; Hartland W Jackson; Valbona Luga; Hui Fang; Sam D Molyneux; Yang W Shao; Alison Aiken; Paul D Waterhouse; Christina Karamboulas; Franz M Hess; Takashi Ohtsuka; Yasunori Okada; Laurie Ailles; Andreas Ludwig; Jeffrey L Wrana; Thomas Kislinger; Rama Khokha
Journal:  Nat Cell Biol       Date:  2014-08-24       Impact factor: 28.824

Review 3.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

4.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

5.  Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.

Authors:  H Cui; B Seubert; E Stahl; H Dietz; U Reuning; L Moreno-Leon; M Ilie; P Hofman; H Nagase; B Mari; A Krüger
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Tissue Inhibitor of Metalloprotease-2 (TIMP-2): Bioprocess Development, Physicochemical, Biochemical, and Biological Characterization of Highly Expressed Recombinant Protein.

Authors:  Anandã Chowdhury; Robert Brinson; Beiyang Wei; William G Stetler-Stevenson
Journal:  Biochemistry       Date:  2017-11-28       Impact factor: 3.162

Review 7.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

Review 8.  The novel role of miRNAs for tamoxifen resistance in human breast cancer.

Authors:  Wenwen Zhang; Jing Xu; Yaqin Shi; Qian Sun; Qun Zhang; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2015-03-18       Impact factor: 9.261

9.  Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.

Authors:  Toshiaki Shinojima; Qiang Yu; Sharon K Huang; Michelle Li; Ryuichi Mizuno; Edison T Liu; Dave S B Hoon; Laurent Lessard
Journal:  Epigenetics       Date:  2012-09-28       Impact factor: 4.528

10.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.